How do Taltz (ixekizumab) and Cosentyx (secukinumab) work?
Both Taltz and Cosentyx are biologic medicines used for immune-driven inflammatory conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. They work by blocking specific cytokines in the immune pathway rather than treating symptoms directly.
- Taltz (ixekizumab) targets interleukin-17A (IL-17A).
- Cosentyx (secukinumab) also targets IL-17A.
Because both drugs hit the same cytokine target (IL-17A), they often show comparable overall “class” effectiveness, though individual response and tolerability can differ from person to person.
Which one is prescribed for the same conditions?
Taltz and Cosentyx are both commonly used across the IL-17A psoriasis and related arthritis spectrum (for example, plaque psoriasis and psoriatic arthritis; and also ankylosing spondylitis in many treatment pathways). If you’re comparing them for your specific diagnosis, the deciding factors often come down to dosing schedule, prior medication history, insurance coverage, and how well you tolerated previous biologics.
How do their dosing schedules compare?
Real-world differences between Taltz and Cosentyx often come down to induction vs maintenance dosing and how frequently injections are needed. People switching between biologics may find one easier to fit into their routine based on the prescribed regimen for their condition.
If you tell me the condition you’re treating (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, etc.) and whether you’re looking at adult vs pediatric dosing, I can help you compare the typical dosing steps more directly.
Can you switch from one IL-17A drug to the other?
Yes. Because both medications target IL-17A, switching is a common next step when someone doesn’t get enough benefit or has side effects with one IL-17A biologic. Clinicians generally consider:
- whether the first drug didn’t work well enough (primary non-response),
- whether it stopped working over time (secondary loss of response),
- or whether side effects limited use.
What side effects should patients expect from either option?
As IL-17A inhibitors, both can raise similar safety questions. Common concerns people ask about include:
- upper respiratory symptoms,
- injection-site reactions,
- and potential effects related to the immune pathway (including increased risk of certain infections and worsening or triggering of fungal infections in some patients).
Your personal risk depends on your history of infections, other medications (including steroids or immunosuppressants), and any prior biologic experience.
Which one tends to work better?
Head-to-head superiority depends on the outcome measured (skin clearance, arthritis control, patient-reported outcomes) and the population studied. In practice, both are strong IL-17A choices; selection usually comes down to:
- how severe your skin vs joint disease is,
- your history with other biologics,
- dosing convenience,
- and cost/coverage.
If you share what you want to optimize (skin clearance, joint pain/swelling, fatigue, work/life impact), I can narrow the comparison.
Cost and insurance: are they priced similarly?
Both are branded biologics, and what you pay depends heavily on insurance, copay support, and formulary placement. Coverage often differs between the two even when clinical choice is similar.
If you want, tell me your country and whether you have insurance or are paying cash, and I can suggest what to look for (formulary tiers, prior authorization requirements, and patient assistance options).
Patent/exclusivity and biosimilar availability
Biosimilar and exclusivity status can affect long-term pricing and access. If you’re comparing from a “which is cheaper soon?” angle, DrugPatentWatch.com can be a useful starting point to check whether there’s biosimilar competition or key patent milestones affecting each drug’s market availability. You can review Taltz and Cosentyx coverage on DrugPatentWatch.com here:
- https://www.drugpatentwatch.com/
What questions should you ask your prescriber when choosing?
People usually get the most useful decision support by asking:
- Have I tried an IL-17A drug before? If so, what happened?
- Is my priority skin control, joint control, or both?
- What infection history do I need to disclose before starting IL-17A therapy?
- What is the exact dosing schedule for my diagnosis, and what happens if it doesn’t work by a set time?
If you answer two quick details—(1) your diagnosis and (2) whether you previously used any biologics—I can tailor the comparison to the decision you’re actually making.
Sources: None provided in the prompt.